Literature DB >> 3162772

Plasma prostaglandin E2 level in Kawasaki disease.

T Lee1, S Furukawa, Y Fukuda, K Yabuta, H Kato.   

Abstract

Plasma levels of prostaglandin E2 and prostaglandin F2 alpha were determined in 15 patients in the acute and recovery stages of Kawasaki disease, 10 patients with anaphylactoid purpura, 16 with bacterial and viral infections and 10 healthy children. Plasma levels of prostaglandin E2 were markedly increased in the acute stage of Kawasaki disease, and these levels were decreased in the recovery stage. The prostaglandin F2 alpha/prostaglandin E2 ratio in the acute stage of Kawasaki disease was markedly decreased. Plasma levels of prostaglandin E2 in patients with anaphylactoid purpura, bacterial and viral infections were within the normal range. In Kawasaki disease which is associated with systemic vasculitis with a severe inflammatory reaction, prostaglandin E2 is considered to be more selectively produced and released than prostaglandin F2 alpha, suggesting that prostaglandin E2 plays an important role in the immunological and inflammatory reaction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3162772     DOI: 10.1016/0952-3278(88)90076-2

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  7 in total

1.  Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease.

Authors:  Youngho Lee; Danica J Schulte; Kenichi Shimada; Shuang Chen; Timothy R Crother; Norika Chiba; Michael C Fishbein; Thomas J A Lehman; Moshe Arditi
Journal:  Circulation       Date:  2012-02-23       Impact factor: 29.690

2.  Angiogenesis in fatal acute Kawasaki disease coronary artery and myocardium.

Authors:  A F Freeman; S E Crawford; M L Cornwall; F L Garcia; S T Shulman; A H Rowley
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

3.  Decreased interferon-gamma (IFN-gamma)-producing T cells in patients with acute Kawasaki disease.

Authors:  T Matsubara; K Katayama; T Matsuoka; M Fujiwara; M Koga; S Furukawa
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

4.  A Comprehensive Update on Kawasaki Disease Vasculitis and Myocarditis.

Authors:  Priya R Soni; Magali Noval Rivas; Moshe Arditi
Journal:  Curr Rheumatol Rep       Date:  2020-02-05       Impact factor: 4.686

5.  Identification of rare coding variants associated with Kawasaki disease by whole exome sequencing.

Authors:  Jae-Jung Kim; Young Mi Hong; Sin Weon Yun; Kyung-Yil Lee; Kyung Lim Yoon; Myung-Ki Han; Gi Beom Kim; Hong-Ryang Kil; Min Seob Song; Hyoung Doo Lee; Kee Soo Ha; Hyun Ok Jun; Byung-Ok Choi; Yeon-Mok Oh; Jeong Jin Yu; Gi Young Jang; Jong-Keuk Lee
Journal:  Genomics Inform       Date:  2021-12-31

6.  Plasma Prostaglandin E2 Levels Correlated with the Prevention of Intravenous Immunoglobulin Resistance and Coronary Artery Lesions Formation via CD40L in Kawasaki Disease.

Authors:  Ho-Chang Kuo; Chih-Lu Wang; Kuender D Yang; Mao-Hung Lo; Kai-Sheng Hsieh; Sung-Chou Li; Ying-Hsien Huang
Journal:  PLoS One       Date:  2016-08-15       Impact factor: 3.240

7.  Insights into pediatric multi-system inflammatory syndrome and COVID-19.

Authors:  David Bar-Or; Leonard T Rael; Edward N Brody
Journal:  Clin Chim Acta       Date:  2020-07-14       Impact factor: 3.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.